Pierre Lovinfosse1, Zsolt Levente Janvary2, Philippe Coucke2, Sébastien Jodogne3, Claire Bernard4, Mathieu Hatt5, Dimitris Visvikis5, Nicolas Jansen2, Bernard Duysinx6, Roland Hustinx4. 1. Department of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, CHU University of Liège, B35 Domaine Universitaire du Sart Tilman, 4000, Liege, Belgium. pierre.lovinfosse@chu.ulg.ac.be. 2. Department of Medical Physics, Division of Radiation Oncology, CHU and University of Liège, Liège, Belgium. 3. Department of Medical Physics, CHU of Liège, Liège, Belgium. 4. Department of Medical Physics, Division of Nuclear Medicine and Oncological Imaging, CHU University of Liège, B35 Domaine Universitaire du Sart Tilman, 4000, Liege, Belgium. 5. LaTIM, INSERM UMR 1101, Brest, France. 6. Division of Pulmonology, CHU Liège, Liège, Belgium.
Abstract
INTRODUCTION: With (18)F-FDG PET/CT, tumor uptake intensity and heterogeneity have been associated with outcome in several cancers. This study aimed at investigating whether (18)F-FDG uptake intensity, volume or heterogeneity could predict the outcome in patients with non-small cell lung cancers (NSCLC) treated by stereotactic body radiation therapy (SBRT). METHODS: Sixty-three patients with NSCLC treated by SBRT underwent a (18)F-FDG PET/CT before treatment. Maximum and mean standard uptake value (SUVmax and SUVmean), metabolic tumoral volume (MTV), total lesion glycolysis (TLG), as well as 13 global, local and regional textural features were analysed. The predictive value of these parameters, along with clinical features, was assessed using univariate and multivariate analysis for overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS). Cutoff values were obtained using logistic regression analysis, and survivals were compared using Kaplan-Meier analysis. RESULTS: The median follow-up period was 27.1 months for the entire cohort and 32.1 months for the surviving patients. At the end of the study, 25 patients had local and/or distant recurrence including 12 who died because of the cancer progression. None of the clinical variables was predictive of the outcome, except age, which was associated with DFS (HR 1.1, P = 0.002). None of the (18)F-FDG PET/CT or clinical parameters, except gender, were associated with OS. The univariate analysis showed that only dissimilarity (D) was associated with DSS (HR = 0.822, P = 0.037), and that several metabolic measurements were associated with DFS. In multivariate analysis, only dissimilarity was significantly associated with DSS (HR = 0.822, P = 0.037) and with DFS (HR = 0.834, P < 0.01). CONCLUSION: The textural feature dissimilarity measured on the baseline (18)F-FDG PET/CT appears to be a strong independent predictor of the outcome in patients with NSCLC treated by SBRT. This may help selecting patients who may benefit from closer monitoring and therapeutic optimization.
INTRODUCTION: With (18)F-FDG PET/CT, tumor uptake intensity and heterogeneity have been associated with outcome in several cancers. This study aimed at investigating whether (18)F-FDG uptake intensity, volume or heterogeneity could predict the outcome in patients with non-small cell lung cancers (NSCLC) treated by stereotactic body radiation therapy (SBRT). METHODS: Sixty-three patients with NSCLC treated by SBRT underwent a (18)F-FDG PET/CT before treatment. Maximum and mean standard uptake value (SUVmax and SUVmean), metabolic tumoral volume (MTV), total lesion glycolysis (TLG), as well as 13 global, local and regional textural features were analysed. The predictive value of these parameters, along with clinical features, was assessed using univariate and multivariate analysis for overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS). Cutoff values were obtained using logistic regression analysis, and survivals were compared using Kaplan-Meier analysis. RESULTS: The median follow-up period was 27.1 months for the entire cohort and 32.1 months for the surviving patients. At the end of the study, 25 patients had local and/or distant recurrence including 12 who died because of the cancer progression. None of the clinical variables was predictive of the outcome, except age, which was associated with DFS (HR 1.1, P = 0.002). None of the (18)F-FDG PET/CT or clinical parameters, except gender, were associated with OS. The univariate analysis showed that only dissimilarity (D) was associated with DSS (HR = 0.822, P = 0.037), and that several metabolic measurements were associated with DFS. In multivariate analysis, only dissimilarity was significantly associated with DSS (HR = 0.822, P = 0.037) and with DFS (HR = 0.834, P < 0.01). CONCLUSION: The textural feature dissimilarity measured on the baseline (18)F-FDG PET/CT appears to be a strong independent predictor of the outcome in patients with NSCLC treated by SBRT. This may help selecting patients who may benefit from closer monitoring and therapeutic optimization.
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Mischa S Hoogeman; John Praag; Bronno van der Holt; Peter C Levendag; Robertus J van Klaveren; Peter Pattynama; Joost J Nuyttens Journal: Radiother Oncol Date: 2009-03-16 Impact factor: 6.280
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Charles C Vu; Robert Matthews; Bong Kim; Dinko Franceschi; Thomas V Bilfinger; William H Moore Journal: Nucl Med Commun Date: 2013-10 Impact factor: 1.690
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Zachary D Horne; David A Clump; John A Vargo; Samir Shah; Sushil Beriwal; Steven A Burton; Annette E Quinn; Matthew J Schuchert; Rodney J Landreneau; Neil A Christie; James D Luketich; Dwight E Heron Journal: Radiat Oncol Date: 2014-01-30 Impact factor: 3.481
Authors: Shulong Li; Ning Yang; Bin Li; Zhiguo Zhou; Hongxia Hao; Michael R Folkert; Puneeth Iyengar; Kenneth Westover; Hak Choy; Robert Timmerman; Steve Jiang; Jing Wang Journal: Med Image Anal Date: 2018-09-15 Impact factor: 8.545